NCT00222833View on ClinicalTrials.gov

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
OverweightHyperlipidemiaCardiovascular Diseases
Interventions
DRUG

Aripiprazole

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic of UPMC, Pittsburgh

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00222833 - The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia | Biotech Hunter | Biotech Hunter